Search results for "ibi"

showing 10 items of 13473 documents

Role of Hypoxia and the Adenosine System in Immune Evasion and Prognosis of Patients with Brain Metastases of Melanoma: A Multiplex Whole Slide Immun…

2020

Simple Summary The introduction of immune-checkpoint inhibitors improved the therapeutic landscape for patients with advanced malignant melanoma. However, many patients, including patients with melanoma brain metastases, do not derive benefit from immune-checkpoint blockade. Hence, biomarkers are needed to identify potential mechanisms of resistance and optimize patient selection. This study aimed to explore the role of hypoxia-mediated immunosuppression within the tumor microenvironment of patients with metastatic melanoma using multiplex immunofluorescence. We analyzed the prognostic relevance of the hypoxia surrogate marker GLUT-1, the adenosine-synthesizing ectoenzymes CD73/CD39, and th…

0301 basic medicineCancer Researchmultiplex immunohistochemistrymedicine.medical_treatmentimmune checkpoint inhibitorIpilimumablcsh:RC254-282Articlespatial statistics03 medical and health sciences0302 clinical medicineImmune systemmedicineCytotoxic T celltumor microenvironmentipilimumabradiotherapyTumor microenvironmentimmunosuppressionbusiness.industryhypoxiaMelanomaImmunosuppressionmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCTL*030104 developmental biologyOncologyadenosine030220 oncology & carcinogenesisCancer researchbusinessCD8medicine.drugCancers
researchProduct

Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy

2019

International audience; One of the main characteristics of carcinogenesis relies on genetic alterations in DNA and epigenetic changes in histone and non-histone proteins. At the chromatin level, gene expression is tightly controlled by DNA methyl transferases, histone acetyltransferases (HATs), histone deacetylases (HDACs), and acetyl-binding proteins. In particular, the expression level and function of several tumor suppressor genes, or oncogenes such as c-Myc, p53 or TRAIL, have been found to be regulated by acetylation. For example, HATs are a group of enzymes, which are responsible for the acetylation of histone proteins, resulting in chromatin relaxation and transcriptional activation,…

0301 basic medicineCancer Researchtumor necrosis factor (TNF)TRAILReviewmedicine.disease_causelcsh:RC254-282Chromatin remodelingchromatin remodeling03 medical and health sciences0302 clinical medicinemedicinetumor necrosis factor (TNF).[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular Biologycancer[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyEpigeneticsHistone Acetyltransferasesbiologyhistone deacetylase (HDAC)lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthChromatin030104 developmental biologyHistonehistone deacetylase inhibitors (HDACIs)OncologyAcetylation030220 oncology & carcinogenesissilencingCancer researchbiology.proteinHistone deacetylasemethylationCarcinogenesisCancers
researchProduct

Integrative analysis of key candidate genes and signaling pathways in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy by bioinformatics

2020

Summary Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), the first immune checkpoint to be targeted clinically, has provided an effective treatment option for various malignancies. However, the clinical advantages associated with CTLA-4 inhibitors can be offset by the potentially severe immune-related adverse events (IRAEs), including autoimmune thyroid dysfunction. To investigate the candidate genes and signaling pathways involving in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy, integrated differentially expressed genes (DEGs) were extracted from the intersection of genes from Gene Expression Omnibus (GEO) datasets and text mining. The functional enrichment was perfo…

0301 basic medicineCandidate geneCD74Signaling pathway.FCGR2BDifferentially expressed geneBiologyBioinformaticsHyperthyroidismAutoimmune Diseases03 medical and health sciencesMice0302 clinical medicineHypothyroidismmedicineAnimalsHumansPharmacology (medical)CTLA-4 AntigenProtein Interaction MapsKEGGGeneImmune Checkpoint InhibitorsPharmacologyPreclinical StudiesSignaling pathwayCancerComputational Biologymedicine.diseaseImmune checkpointGene Expression Regulation Neoplastic030104 developmental biologyGene OntologyAutoimmune thyroid dysfunctionOncologyCTLA-4030220 oncology & carcinogenesisDifferentially expressed genesCTLA-4BiomarkersImmune checkpoint blockadeSignal Transduction
researchProduct

Genetic susceptibility to angiotensin-converting enzyme-inhibitor induced angioedema: A systematic review and evaluation of methodological approaches.

2019

Angiotensin-converting enzyme (ACE) converts angiotensin I to angiotensin II which causes vasoconstriction. ACE inhibitors reduce blood pressure by inhibiting ACE. A well-known adverse drug reaction to ACE inhibitors is ACE inhibitor-induced angioedema (ACEi-AE). Angioedema is a swelling of skin and mucosa, which can be fatal if the airway is compromised. We have performed a systematic review of the evidence suggesting that genetic polymorphisms are associated with ACEi-AE and evaluated the methodological approaches of the included studies. The Cochrane Database of Systematic Reviews, Google Scholar, and PubMed were searched. Studies investigating the association between genetic markers and…

0301 basic medicineCandidate geneHeredityACE inhibitorsGenome-wide association studyAngiotensin-Converting Enzyme InhibitorsBioinformatics030226 pharmacology & pharmacyBiochemistryDatabase and Informatics Methods0302 clinical medicineOutcome Assessment Health CareMedicine and Health SciencesDatabase SearchingMultidisciplinarybiologyQRDrugsEnzyme inhibitorsGenomicsResearch AssessmentGenetic MappingSystematic reviewResearch DesignMedicinemedicine.symptomResearch ArticleSystematic ReviewsScienceResearch and Analysis Methods03 medical and health sciencesAdverse ReactionsGenetic predispositionmedicineGenome-Wide Association StudiesGeneticsHumansGenetic Predisposition to DiseaseAngioedemaPharmacologyEvolutionary BiologyPolymorphism GeneticAngioedemaBiology and life sciencesPopulation Biologybusiness.industryCase-control studyComputational BiologyCorrectionAngiotensin-converting enzymeHuman GeneticsGenome AnalysisAngiotensin II030104 developmental biologyHaplotypesCase-Control Studiesbiology.proteinEnzymologyGenetic PolymorphismbusinessPopulation GeneticsPloS one
researchProduct

Singular Location and Signaling Profile of Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Dorsal Striatum

2018

The dorsal striatum is a key node for many neurobiological processes such as motor activity, cognitive functions, and affective processes. The proper functioning of striatal neurons relies critically on metabotropic receptors. Specifically, the main adenosine and endocannabinoid receptors present in the striatum, ie, adenosine A(2A) receptor (A(2A)R) and cannabinoid CB1 receptor (CB1R), are of pivotal importance in the control of neuronal excitability. Facilitatory and inhibitory functional interactions between striatal A(2A)R and CB1R have been reported, and evidence supports that this cross-talk may rely, at least in part, on the formation of A(2A)R-CB1R heteromeric complexes. However, th…

0301 basic medicineCannabinoid receptorAdenosineReceptor Adenosine A2Amedicine.medical_treatmentAdenosinaAdenosine A2A receptormediated inhibitionStriatumBiologyhuntingtons-disease micecannabinoid CB1Mice03 medical and health sciencesglutamatergic neurotransmission0302 clinical medicineReceptor Cannabinoid CB1NeurobiologyNeural PathwaysBasal gangliamedicineAnimalsHumansendocannabinoid systemGenetically modified animalProtein Structure QuaternaryA(2A) receptorsPharmacologyEndocannabinoid systemCorpus Striatumprotein-coupled receptorsProtein SubunitsPsychiatry and Mental healthtransgenic mouse modelHuntington Disease030104 developmental biologyMetabotropic receptornervous systembasal gangliaCannabinoidallosteric interactionsNeuroscience030217 neurology & neurosurgeryNeurobiologiaSignal Transduction
researchProduct

Resistance profiles and risk factors of resistant microorganisms in bacteraemia of abdominal origin

2017

Abstract Objective The presence of resistant microorganisms is a major cause of failure in initial empirical antimicrobial therapy. The objectives of this study are to determine the resistance profile of microorganisms that cause bacteraemia of abdominal origin and to identify whether the previous use of antibiotics and the place of acquisition of bacteraemia are risk factors associated with the presence of resistant organisms. Material and methods A clinical, observational, epidemiological, retrospective cohort study was conducted with all the adult patients admitted to a university hospital from 2011 to 2013. Antimicrobial resistance profiles were described and a 95% confidence interval c…

0301 basic medicineCarbapenembiologybusiness.industrymedicine.drug_class030106 microbiologyAntibioticsGeneral Medicinebacterial infections and mycosesmedicine.disease_causeAntimicrobialbiology.organism_classificationCandida parapsilosisMethicillin-resistant Staphylococcus aureusMicrobiology03 medical and health scienceschemistry.chemical_compoundAntibiotic resistancechemistryCandida kruseiLinezolidmedicinebusinessmedicine.drugRevista Española de Anestesiología y Reanimación (English Edition)
researchProduct

Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resi…

2020

Ceftazidime-avibactam (CZA) is a novel beta-lactam beta-lactamase inhibitor combination approved for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and for hospital-acquired/ventilator-associated pneumonia. The aim of this systematic review (PROSPERO registration number: CRD42019128927) was to evaluate the effectiveness of CZA combination therapy versus CZA monotherapy in the treatment of severe infections. The databases included in the search, until February 12th, 2020, were MEDLINE by PubMed, EMBASE, and The Cochrane Central Register of Controlled Trials. We included both randomized controlled trials (RCTs) and non-randomized studies publish…

0301 basic medicineCarbapenem-resistant enterobacteriaceaeBiochemistrylaw.inventionsepsisCeftazidime‐avibactam0302 clinical medicineRandomized controlled trialsystematic reviewlawPharmacology (medical)030212 general & internal medicineGeneral Pharmacology Toxicology and Pharmaceuticsnetwork meta-analysisceftazidime-avibactamAnti‐infective agentnetwork meta-analysiInfectious Diseasescarbapenem-resistant EnterobacteriaceaeMeta-analysisβ-lactamase inhibitors.sepsimedicine.drugMicrobiology (medical)medicine.medical_specialtyCombination therapyβ-lactamase inhibitors030106 microbiologyMEDLINEβ‐lactamase inhibitorsMicrobiologyArticle03 medical and health sciencesCarbapenem‐resistant Enterobacteriaceaemultidrug resistanceInternal medicinemedicineanti-infective agentbacteremiabusiness.industrylcsh:RM1-950Retrospective cohort studyCeftazidime/avibactammedicine.diseaseinfectionlcsh:Therapeutics. PharmacologyBacteremiaanti-infective agentsbusinessNetwork meta‐analysi
researchProduct

Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs)

2017

This paper describes the development of a class of peptide-based inhibitors as novel antitrypanosomal and antimalarial agents. The inhibitors are based on a characteristic peptide sequence for the inhibition of the cysteine proteases rhodesain of Trypanosoma brucei rhodesiense and falcipain-2 of Plasmodium falciparum. We exploited the reactivity of novel unsaturated electrophilic functions such as vinyl-sulfones, -ketones, -esters, and -nitriles. The Michael acceptors inhibited both rhodesain and falcipain-2, at nanomolar and micromolar levels, respectively. In particular, the vinyl ketone 3b has emerged as a potent rhodesain inhibitor (k2nd = 67 × 106 M-1 min-1), endowed with a picomolar b…

0301 basic medicineCathepsin LAntimalarialPeptideHeLa Cell01 natural sciencesCysteine Proteinase InhibitorDipeptideDrug DiscoveryPeptide sequencechemistry.chemical_classificationTrypanocidal AgentbiologyNeglected DiseasesStereoisomerismDipeptidesTrypanocidal AgentsMAJOR CYSTEINE PROTEASE PLASMODIUM-FALCIPARUM TRYPANOSOMA-BRUCEI CONFORMATIONAL-ANALYSIS BIOLOGICAL EVALUATION HIGHLY POTENT VINYL-ESTER INHIBITORS PEPTIDOMIMETICS SUBSTRATEMolecular Docking SimulationCysteine EndopeptidasesBiochemistryMolecular MedicineHumanProteasesNeglected DiseaseStereochemistryPhenylalaninePlasmodium falciparumTrypanosoma brucei bruceiCysteine Proteinase InhibitorsMolecular Dynamics SimulationTrypanosoma bruceiAntimalarialsStructure-Activity Relationship03 medical and health sciencesparasitic diseasesHumansStructure–activity relationship010405 organic chemistryDrug Discovery3003 Pharmaceutical ScienceHydrogen BondingTrypanosoma brucei rhodesiensePlasmodium falciparumbiology.organism_classificationMalaria0104 chemical sciencesTrypanosomiasis African030104 developmental biologychemistryCarbamateCarbamatesCysteine EndopeptidaseHeLa CellsCysteineJournal of Medicinal Chemistry
researchProduct

Cytotoxic effects induced by patulin, deoxynivalenol and toxin T2 individually and in combination in hepatic cells (HepG2).

2018

Abstract Patulin (PAT), deoxynivalenol (DON) and toxin T-2 (T-2) are mycotoxins distributed worldwide in food and feed. Cytotoxicity of the three mycotoxins individually or in combination in human hepatocellular carcinoma (HepG2) cells was evaluated by MTT assay over 24, 48 and 72 h of exposure. The concentration ranges used were 0.625–15 μM for DON, 1.25–50 nM for T-2 and 0.45–7.5 μM for PAT. The IC 50 values obtained ranged from 9.30 to 2.53 μM, from 33.69 to 44.37 nM and from 2.66 to 1.17 μM for DON, T-2 and PAT, respectively. The most cytotoxic mycotoxin to HepG2 cells was T-2 followed by PAT and DON. The combination ratios used for the mixtures were 1:3 (DON: T-2), 1:5 (DON: PAT), 1:1.…

0301 basic medicineCell SurvivalComplex MixturesToxicologymedicine.disease_causePatulin03 medical and health scienceschemistry.chemical_compoundInhibitory Concentration 500404 agricultural biotechnologymedicineCytotoxic T cellHumansMTT assayDrug InteractionsCytotoxicityMycotoxinDose-Response Relationship DrugToxin04 agricultural and veterinary sciencesGeneral MedicineHep G2 CellsMycotoxinsmedicine.disease040401 food scienceMolecular biologyDrug CombinationsT-2 Toxin030104 developmental biologyPatulinchemistryLiverHepatocellular carcinomaHepatic stellate cellTrichothecenesFood ScienceFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association
researchProduct

Imatinib-Loaded Micelles of Hyaluronic Acid Derivatives for Potential Treatment of Neovascular Ocular Diseases

2018

In this work, new micellar systems able to cross corneal barrier and to improve the permeation of imatinib free base were prepared and characterized. HA-EDA-C-16, HA-EDA-C-16-PEG, and HA-EDA-C-16-CRN micelles were synthesized starting from hyaluronic acid (HA), ethylenediamine (EDA), hexadecyl chains (C-16), polyethylene glycol (PEG), or L-carnitine (CRN). These nanocarriers showed optimal particle size and mucoadhesive properties. Imatinib-loaded micelles were able to interact with corneal barrier and to promote imatinib transcorneal permeation and penetration. In addition, a study was conducted to understand the in vitro imatinib inhibitory effect on a choroidal neovascularization process…

0301 basic medicineCell SurvivalDrug CompoundingPharmaceutical ScienceAdministration Ophthalmic02 engineering and technologyPolyethylene glycolMicellePermeabilityCell LinePolyethylene GlycolsCornea03 medical and health scienceschemistry.chemical_compoundocular drug delivery hyaluronic acid polymeric micelles imatinib transcorneal permeation ocular neovascular diseasesCarnitinehemic and lymphatic diseasesDrug DiscoveryHyaluronic acidPEG ratiomedicineocular drug delivery; hyaluronic acid; polymeric micelles; imatinib; transcorneal permeation; ocular neovascular diseasesAnimalsHumansHyaluronic AcidParticle SizeProtein Kinase InhibitorsneoplasmsMicellesDrug CarriersEndothelial CellsImatinibPermeation021001 nanoscience & nanotechnologyEthylenediaminesIn vitroChoroidal NeovascularizationDrug Liberation030104 developmental biologychemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoBiophysicsImatinib MesylateMolecular Medicinelipids (amino acids peptides and proteins)CattleNanocarriers0210 nano-technologymedicine.drug
researchProduct